CanNOT overstate the pivotal impact of all of Dr. Temel’s work including on digital palliative care model, esp as we in parallel improve the survival of pts with lung cancer. Come hear her invaluable insights - room 30a, happening now #WCLC24 #LCSM IASLC

Come visit the poster presenters at the Exhibit Hall, happening now! Lots of great work being shared, including by Sarah Waliany, MD, MS , super talented senior fellow from MGH Thoracic Oncology on ALK TKI resistance large dataset analysis. #WCLC24 #LCSM ALK Positive ALK+ International

No better way to start the day after a IASLC 50 year celebration than a fun quiz session on targets by Stephen V Liu, MD Ben Solomon and Natasha Leighl. Guaranteed to be fun and instructive. Room 33! #WCLC24

The incredible Janet Freeman-Daily on why researchers can't afford to NOT include patient research advocates in their studies throughout the whole process. She closes with this: we do it because we are tired of seeing our friends die, and to find meaning in suffering #WCLC2024

Some really great poster walks at #WCLC24 with Drs. Gerry Hanna Jonathan Riess, MD MS Prunella Blinman Melissa L. Johnson Sarah Waliany, MD, MS - great opportunities for small group discussions!

Just listened to this terrific #WCLC24 Highlights Korean Podcast by Chul Kim. Tremendous value to having #LungCancerConsidered podcast in multiple non-English languages, allowing different flavors of medical culture & communication to be captured while important scientific

#WCLC24 DANIEK C. IHDE LECTURESHIP AWARD for MEDICAL ONCOGY goes to Dr. Solange Peters Solange Peters. Your passion and relentless work inspire us all.

Dr. Jeff Yang MD FACS is a brilliant investigator, surgeon and fantastic colleague. Wonderful to see him and his team and their work recognized today at #WCLC24 with the Clifton F. Mountain Lectureship Award for Staging.

Congratulations Jeff Yang MD FACS on your well deserved recognition by IASLC w the Cliff Mountain staging award. Your lecture meaningfully demonstrated how staging is a language we share w each other, with patients and with the public. You and ALCSI are inspiring a generation!

Dr. Geoffrey Liu presents data from TRUST-II, global phase II trial evaluating next-gen ROS1 TKI taletrectinib in patients with ROS1 NSCLC. PFS data - esp in 1L setting - awaited. Looking forward to additional data to be shared next week at ESMO. #WCLC24 The ROS1ders, Inc. IASLC

Dr. Tony Mok shares additional insights from CROWN, on pts w/ ALK+ nsclc who progressed early vs late on 1L lorlatinib, subsequent therapies. Critical to have these updates as the follow-up increases. #WCLC24 IASLC ALK Positive ALK+ International

Helpful and highly clinically relevant insights presented by Dr. Todd Bauer on the kinetics and management of AEs on 1L lorlatinib in the CROWN trial. Continued updates important for patients, caregivers, clinicians. #WCLC24 IASLC ALK Positive ALK+ International

1/4 Alright, so here are my thoughts on Radiation to Residual Disease after Targeted Therapies as presented at #WCLC24. Focusing on EGFR mutant #lungcancer where we all agree, I think, that osimertinib alone cannot be the answer, right⁉️🧐 The main risk here is secondary